Immatics combines the discovery of cancer targets with T cell receptor development to create Adoptive Cell Therapies and TCR Bispecifics.
PRAME is a target expressed in more than 50 cancers, including melanoma, lung, ovarian, breast, and endometrial cancer, among many others. Targeting PRAME unlocks new treatment options for a broad patient population with significant unmet medical need.
The company is advancing targeted PRAME cell therapies and bispecific product candidates through clinical trials, aiming to bring innovative cancer treatments from lab to clinic.
